These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 17696240)

  • 1. Clearance of hepatitis C virus after living-donor liver transplantation in spite of residual viremia on end date of interferon therapy before transplantation.
    Ichikawa T; Nakao K; Hamasaki K; Honda T; Shibata H; Akahoshi M; Eguchi S; Takatsuki M; Kanematsu T; Eguchi K
    World J Gastroenterol; 2007 Aug; 13(30):4149-51. PubMed ID: 17696240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two patients treated with simeprevir plus pegylated-interferon and ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation: case report.
    Kawaoka T; Imamura M; Kan H; Fujino H; Fukuhara T; Kobayashi T; Honda Y; Naeshiro N; Hiramatsu A; Tsuge M; Hayes CN; Kawakami Y; Aikata H; Ochi H; Ishiyama K; Tashiro H; Ohdan H; Chayama K
    Transplant Proc; 2015 Apr; 47(3):809-14. PubMed ID: 25891736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical outcome after living donor liver transplantation in patients with hepatitis C virus-associated cirrhosis].
    Park JI; Choi KM; Lee SG; Hwang S; Kim KH; Ahn CS; Moon DB; Chung YH; Lee YS; Suh DJ
    Korean J Hepatol; 2007 Dec; 13(4):543-55. PubMed ID: 18159152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.
    Faisal N; Mumtaz K; Marquez M; Renner EL; Lilly LB
    Hepatol Int; 2015 Jan; 9(1):76-83. PubMed ID: 25788382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse.
    Gerotto M; Dal Pero F; Bortoletto G; Ferrari A; Pistis R; Sebastiani G; Fagiuoli S; Realdon S; Alberti A
    J Hepatol; 2006 Jan; 44(1):83-7. PubMed ID: 16271794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of hepatitis C virus recurrence after living donor liver transplantation: Mansoura experience.
    Abdel-Wahab M; Abdel-Khalek EE; El-Gilany AH; Yassen AM; Al-Shobari M; Shiha U; Ali M; Sadani M; Salah T; Sultan AM; Elghawalby AN; Elmorshedi M; Al-Refaey AK; Abdalla U
    Arab J Gastroenterol; 2017 Sep; 18(3):151-155. PubMed ID: 28958486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Section 13. Short-course pretransplant antiviral therapy is a feasible and effective strategy to prevent hepatitis C recurrence after liver transplantation in genotype 2 patients.
    Lin CC; Kabiling C; Chen CL; Lin YH; Liu YW; Wang CC; Hu TH; Chiu KW
    Transplantation; 2014 Apr; 97 Suppl 8():S47-53. PubMed ID: 24849835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current management and perspectives for HCV recurrence after liver transplantation.
    Coilly A; Roche B; Samuel D
    Liver Int; 2013 Feb; 33 Suppl 1():56-62. PubMed ID: 23286847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group.
    Nousbaum JB; Pol S; Nalpas B; Landais P; Berthelot P; Bréchot C
    Ann Intern Med; 1995 Feb; 122(3):161-8. PubMed ID: 7810932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Achievement of sustained viral response after switching treatment from pegylated interferon α-2b to α-2a and ribavirin in patients with recurrence of hepatitis C virus genotype 1 infection after liver transplantation: a case report.
    Kawaoka T; Hiraga N; Takahashi S; Takaki S; Tsuge M; Nagaoki Y; Hashimoto Y; Katamura Y; Miki D; Hiramatsu A; Waki K; Imamura M; Kawakami Y; Aikata H; Ochi H; Tashiro H; Ohdan H; Chayama K
    Intervirology; 2012; 55(4):306-10. PubMed ID: 21865660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
    Zimmermann T; Böcher WO; Biesterfeld S; Zimmermann A; Kanzler S; Greif-Higer G; Barreiros AP; Sprinzl MF; Wörns MA; Lohse AW; Mönch C; Otto G; Galle PR; Schuchmann M
    Transpl Int; 2007 Jul; 20(7):583-90. PubMed ID: 17433090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An escalating dose regimen of pegylated interferon and ribavirin in HCV cirrhotic patients referred for liver transplant.
    Massoumi H; Elsiesy H; Khaitova V; Peterson B; Norkus E; Grewal P; Liu L; Chang C; Bach N; Schiano TD
    Transplantation; 2009 Sep; 88(5):729-35. PubMed ID: 19741473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation.
    Dinges S; Morard I; Heim M; Dufour JF; Müllhaupt B; Giostra E; Clavien PA; Mentha G; Negro F;
    Transpl Infect Dis; 2009 Feb; 11(1):33-9. PubMed ID: 19144096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Living donor liver transplantation for patients with hepatitis C virus cirrhosis: Tokyo experience.
    Sugawara Y; Makuuchi M
    Clin Gastroenterol Hepatol; 2005 Oct; 3(10 Suppl 2):S122-4. PubMed ID: 16234059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
    Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
    Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation.
    Fernández I; Meneu JC; Colina F; García I; Muñoz R; Castellano G; Fuertes A; Abradelo M; Lumbreras C; Moreno E; Solís-Herruzo JA
    Liver Transpl; 2006 Dec; 12(12):1805-12. PubMed ID: 17133585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
    Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
    Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral therapy of symptomatic HCV-mixed cryoglobulinemia after liver transplant: case report and literature review.
    Francesca Donato M; Banfi G; Cresseri D; Battista Fogazzi G; Martin P; Messa P; Fabrizi F
    Int J Artif Organs; 2013 May; 36(5):367-72. PubMed ID: 23446762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis.
    Mira JA; García-Rey S; Rivero A; de los Santos-Gil I; López-Cortés LF; Girón-González JA; Téllez F; Márquez M; Merino D; Ríos-Villegas MJ; Macías J; Rivero-Juárez A; Pineda JA
    Clin Infect Dis; 2012 Dec; 55(12):1719-26. PubMed ID: 22955435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.